Ftse Mib
34.339,32
0,55%
DAX
18.686,60
1,07%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,27%
Bitcoin
62.903,56
-0,23%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ BridgeBio Pharma Inc (BBIO) BridgeBio Pharma Inc (BBIO) Notizie

BridgeBio Pharma Inc

BBIO
28,10
0,40 (1,44%)
10 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/5/202413:30GLOBEBridgeBio Pharma Reports First Quarter 2024 Financial..
02/5/202413:00GLOBEBridgeBio launches BridgeBio Oncology Therapeutics (BBOT)..
10/4/202413:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
07/4/202419:15GLOBEBridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR)..
20/3/202412:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
06/3/202423:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/3/202423:13EDGAR2Form 8-K - Current report
06/3/202405:53GLOBEBridgeBio Pharma Announces Pricing of Public Offering of..
04/3/202423:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/3/202422:17GLOBEBridgeBio Pharma Announces Proposed Public Offering of..
04/3/202413:00EDGAR2Form 8-K - Current report
04/3/202408:30GLOBEBridgeBio Pharma and Bayer Announce European Licensing..
22/2/202422:27EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202413:31EDGAR2Form 8-K - Current report
22/2/202413:30GLOBEBridgeBio Pharma Reports Fourth Quarter and Full Year 2023..
21/2/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202422:06EDGAR2Form 144 - Report of proposed sale of securities
13/2/202422:05EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
13/2/202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202413:34GLOBEBridgeBio Pharma and Kyowa Kirin Announce Partnership with..
06/2/202413:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
05/2/202413:30GLOBEBridgeBio Pharma Announces U.S. Food and Drug Administration..
02/2/202413:00GLOBEBridgeBio Pharma Shares Positive Results of Single-Arm Phase..
30/1/202413:00PRNUSInvitae Partners with BridgeBio Pharma to Harness Genetic..
18/1/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202413:30EDGAR2Form 8-K - Current report
18/1/202413:00GLOBEBridgeBio Pharma Secures up to $1.25 Billion of Capital from..
16/1/202422:04EDGAR2Form 144 - Report of proposed sale of securities
10/1/202423:15GLOBEBridgeBio Pharma Announces Publication of Positive Results..
10/1/202413:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
08/1/202423:14EDGAR2Form 8-K - Current report
05/1/202422:06EDGAR2Form S-8 - Securities to be offered to employees in employee..
03/1/202422:30GLOBEBridgeBio Pharma to Participate in the J.P. Morgan..
03/1/202413:30GLOBEBridgeBio announces FDA clearance of IND application for..
19/12/202322:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:13EDGAR2Form 144 - Report of proposed sale of securities
13/12/202313:30GLOBEBridgeBio Announces First Child Dosed in PROPEL 3, its Phase..
08/12/202313:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
05/12/202314:52DJNBridgeBio Seeks FDA Approval of Acoramidis in Transthyretin..
05/12/202313:44GLOBEBridgeBio Pharma Announces Submission of New Drug..
20/11/202322:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202322:27EDGAR2Form 144 - Report of proposed sale of securities
17/11/202322:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/11/202322:03EDGAR2Form 144 - Report of proposed sale of securities
12/11/202316:30GLOBEBridgeBio Pharma Presents Additional Clinical Outcomes Data..
09/11/202313:30GLOBEBridgeBio Pharma to Present Additional Data from the Phase 3..
08/11/202313:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
02/11/202321:59EDGAR2Form S-3ASR - Automatic shelf registration statement of..
02/11/202312:31EDGAR2Form 8-K - Current report
Apertura: 27,67 Min: 27,38 Max: 28,755
Chiusura: 27,70

La tua Cronologia

NASDAQ
BBIO
BridgeBio Pharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network